➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Dow
Boehringer Ingelheim
Johnson and Johnson
Mallinckrodt

Last Updated: October 26, 2021

DrugPatentWatch Database Preview

Litigation Details for In Re: Actos Direct Purchaser Antitrust Litigation (S.D.N.Y. 2015)


Email this page to a colleague

« Back to Dashboard

Small Molecule Drugs cited in In Re: Actos Direct Purchaser Antitrust Litigation

Details for In Re: Actos Direct Purchaser Antitrust Litigation (S.D.N.Y. 2015)

Date Filed Document No. Description Snippet Link To Document
2015-04-27 1 Patent No. Issue Date Patent Expiry 6,150,383 (the…its patent information that the two patents—United States Patent Nos. 5,965,584 (the “’584 Patent”) and…manufacturer’s patents and patent information for accuracy or trustworthiness. In listing patents and patent information…the ’777 Patent, the ’584 Patent, and the ’404 Patent, Takeda submitted eight other patents to the FDA…the ’584 Patent and the ’404 Patent as drug product patents claiming ACTOS only if the patents in fact External link to document
2019-10-08 131 Memorandum & Opinion two other patents-U.S. Patent Nos. 5,965,584 (the "'584 patent") and 6,329,404 (the "… several patents related to its diabetes medicines. The first of those patents, U.S. Patent. No. 4,687,777…hereinafter, "the Patents") as both drug product patents and method-of-use patents-and improperly … Normally, inventors obtain patents for their brand-name drugs. Patents that protect a drug may include…such patents must be submitted with an NDA is at the heart of this case. For each patent that External link to document
2016-01-06 54 Patent No. Issue Date Patent Expiry 6,150,383 (the…listed three additional patents – the ’042 Patent, the ’043 Patent, and the ’090 Patent – as applicable method-of-use…Takeda asserted in its patent information that the two patents – United States Patent Nos. 5,965,584 (the…misleading patent information regarding the ’584 Met Combo Patent and ’404 Insulin Combo Patent for ACTOS… drug substance patent – U.S. Patent No. 4,687,777 (the “’777 ACTOS Compound Patent”) – expired on January External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
McKesson
Johnson and Johnson
Harvard Business School
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.